Dawson James Reiterates Sorrento Therapeutics (SRNE) at Buy, $16 PT, Sees 70% Chance of Success of Company's COVID Tests and Therapeutics
Tweet Send to a Friend
Dawson James analyst Jason Kolbert reiterated a Buy rating and $16.00 price target on Sorrento Therapeutics (NASDAQ: SRNE).The analyst quotes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
